6.52 +0.03 +0.46%
After-market 06:48:09 PM NAS
Plus500. 81% of retail CFD accounts lose money
6.49 -0.02 -0.31%
Official Close 04:00:00 PM NAS
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Friday 01/26/2024 the closing price of the GoodRx Holdings Inc Registered Shs -A- share was $6.52 on NAS. Compared to the opening price on Friday 01/26/2024 on NAS of $6.47, this is a gain of 0.77%.GoodRx Holdings Inc Registered Shs -A-'s market capitalization is $2.73 B by 92.40 M shares outstanding.
Is GoodRx stock a Buy, Sell or Hold?
GoodRx stock has received a consensus rating of hold. The average rating score is and is based on 22 buy ratings, 48 hold ratings, and 1 sell ratings.What was the 52-week low for GoodRx stock?
The low in the last 52 weeks of GoodRx stock was 4.14. According to the current price, GoodRx is 157.68% away from the 52-week low.What was the 52-week high for GoodRx stock?
The high in the last 52 weeks of GoodRx stock was 9.37. According to the current price, GoodRx is 69.62% away from the 52-week high.What are analysts forecasts for GoodRx stock?
The 71 analysts offering price forecasts for GoodRx have a median target of 11.50, with a high estimate of 35.00 and a low estimate of 4.50. The median estimate represents a 56.71 difference from the last price of 6.52.GoodRx Stock Snapshot
17.81
Bid
500.00
Bid Size
17.93
Ask
500.00
Ask Size
1/26/2024
Date
6:48 PM
Time
761,934.00
Volume
6.49
Prev. Close
6.47
Open
2.73 B
Market Cap
92.40 M
Number of Shares
6.44
Day Low
6.61
Day High
6.52
4.14
52 Week Low
9.37
52 Week High
6.52
0.00
Dividend
15.53
P/E Ratio
80.79
Free Float in %
0.30
EPS 2024
2.22
Book Value per Share
0.36
Cash Flow per Share
GoodRx NewsMore News
Seeking Alpha
GDRX, SSRM and EOLS are among after hour movers
TipRanks
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), GoodRx Holdings (GDRX) and Intuitive Surgical (ISRG)
Zacks
Earnings Estimates Rising for GoodRx Holdings, Inc. (GDRX): Will It Gain?
Zacks
What Makes GoodRx Holdings, Inc. (GDRX) a Strong Momentum Stock: Buy Now?
Zacks
After Golden Cross, GoodRx Holdings, Inc. (GDRX)'s Technical Outlook is Bright
Historical Prices for GoodRx
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
GoodRx Analyst Data
Total Analysts: 71
Buy Ratings: 22 Neutral Ratings: 48 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 4.50 Median: 11.50 Highest: 35.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
GoodRx Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 01/16/24 | RBC Capital Markets | Maintained Hold | $7 | neutral | ||
| 01/02/24 | Bank of America Merrill Lynch | Downgraded to Sell | $4.5 | schlecht | ||
| 11/17/23 | J.P. Morgan | Maintained Hold | $6 | neutral | ||
| 11/13/23 | Goldman Sachs | Maintained Hold | $6 | neutral | ||
| 11/10/23 | RBC Capital Markets | Maintained Hold | $5 | neutral | ||
| 11/10/23 | Goldman Sachs | Maintained Hold | $6 | neutral | ||
| 11/10/23 | Morgan Stanley | Maintained Hold | $5.5 | neutral | ||
| 09/14/23 | J.P. Morgan | Maintained Hold | $7 | neutral | ||
| 08/10/23 | Deutsche Bank | Maintained Hold | $8 | neutral | ||
| 08/10/23 | Guggenheim | Maintained Buy | $10 | gut | ||
| 08/10/23 | J.P. Morgan | Maintained Hold | $6 | neutral | ||
| 08/10/23 | Citigroup Corp. | Maintained Buy | $11 | gut | ||
| 08/10/23 | Evercore | Maintained Hold | $10 | neutral | ||
| 08/10/23 | Goldman Sachs | Maintained Hold | $7 | neutral | ||
| 08/10/23 | Credit Suisse | Maintained Hold | $8 | neutral | ||
| 08/10/23 | RBC Capital Markets | Maintained Hold | $8 | neutral | ||
| 08/10/23 | D.A. Davidson & Co. | Upgraded to Buy | $9.5 | gut | ||
| 08/10/23 | Wells Fargo & Co | Maintained Hold | $7 | neutral | ||
| 07/17/23 | Morgan Stanley | Maintained Hold | $8 | neutral | ||
| 05/11/23 | Bank of America Merrill Lynch | Maintained Buy | $8 | gut | ||
| 05/11/23 | RBC Capital Markets | Maintained Hold | $6 | neutral | ||
| 05/11/23 | Goldman Sachs | Maintained Hold | $6.25 | neutral | ||
| 05/11/23 | Citigroup Corp. | Maintained Buy | $7 | gut | ||
| 03/08/23 | Citigroup Corp. | Maintained Buy | $7.5 | gut | ||
| 03/07/23 | Deutsche Bank | Maintained Hold | $8 | neutral | ||
| 03/02/23 | Credit Suisse | Maintained Hold | $8 | neutral | ||
| 03/02/23 | Wells Fargo & Co | Maintained Hold | $6 | neutral | ||
| 03/01/23 | Goldman Sachs | Maintained Hold | $7 | neutral | ||
| 01/18/23 | Barclays Capital | Maintained Buy | $8 | gut | ||
| 12/01/22 | Citigroup Corp. | Maintained Buy | $7 | gut | ||
| 11/09/22 | Goldman Sachs | Maintained Hold | $8 | neutral | ||
| 11/09/22 | RBC Capital Markets | Maintained Hold | $6 | neutral | ||
| 11/09/22 | Morgan Stanley | Maintained Hold | $6 | neutral | ||
| 11/04/22 | J.P. Morgan | Upgraded to Hold | $8 | neutral | ||
| 10/11/22 | Barclays Capital | Maintained Buy | $9 | gut | ||
| 08/12/22 | D.A. Davidson & Co. | Maintained Hold | $8 | neutral | ||
| 08/10/22 | Morgan Stanley | Maintained Hold | $10 | neutral | ||
| 08/09/22 | Credit Suisse | Maintained Hold | $11 | neutral | ||
| 08/09/22 | Goldman Sachs | Maintained Hold | $10 | neutral | ||
| 08/09/22 | RBC Capital Markets | Maintained Hold | $11 | neutral | ||
| 08/09/22 | Barclays Capital | Maintained Buy | $13 | gut | ||
| 08/09/22 | SVB Leerink | Maintained Hold | $11 | neutral | ||
| 07/20/22 | Barclays Capital | Maintained Buy | $12 | gut | ||
| 07/18/22 | Guggenheim | Maintained Buy | $13 | gut | ||
| 06/23/22 | RBC Capital Markets | Maintained Hold | $6.5 | neutral | ||
| 06/22/22 | Baird Patrick & Co | Maintained Hold | $6 | neutral | ||
| 06/13/22 | Cowen and Company, LLC | Maintained Hold | $9 | neutral | ||
| 06/10/22 | Goldman Sachs | Downgraded to Hold | $9 | neutral | ||
| 06/06/22 | Bank of America Merrill Lynch | Maintained Buy | $11 | gut | ||
| 06/01/22 | Baird Patrick & Co | Downgraded to Hold | $7 | neutral |
GoodRx Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | 789 | 847 | 957 | 1,082 |
| Dividend | 0.00 | 0.00 | 0.00 | - |
| Dividend Yield (in %) | - | - | - | - |
| EPS | 0.30 | 0.37 | 0.49 | 0.61 |
| P/E Ratio | 21.40 | 17.28 | 13.22 | 10.51 |
| EBIT | 163 | 200 | 212 | 348 |
| EBITDA | 225 | 254 | 318 | 402 |
| Net Profit | 21 | 48 | 79 | 142 |
| Net Profit Adjusted | 122 | 157 | 201 | 249 |
| Pre-Tax Profit | 162 | 195 | 261 | 323 |
| Net Profit (Adjusted) | 29 | 52 | 66 | - |
| EPS (Non-GAAP) ex. SOE | 0.30 | 0.37 | 0.49 | 0.61 |
| EPS (GAAP) | 0.05 | 0.11 | 0.19 | 0.35 |
| Gross Income | 723 | 778 | 890 | 978 |
| Cash Flow from Investing | -59 | -47 | -64 | -70 |
| Cash Flow from Operations | 190 | 202 | 265 | 305 |
| Cash Flow from Financing | -20 | -6 | -7 | -7 |
| Cash Flow per Share | 0.36 | 0.31 | -0.07 | - |
| Free Cash Flow | 144 | 181 | 207 | 244 |
| Free Cash Flow per Share | 0.32 | 0.29 | 0.34 | 0.35 |
| Book Value per Share | 2.22 | 2.92 | 1.33 | - |
| Net Debt | -170 | -418 | 105 | 634 |
| Research & Development Exp. | 107 | 112 | 115 | 123 |
| Capital Expenditure | 1 | 1 | 14 | 4 |
| Selling, General & Admin. Exp. | 386 | 415 | - | - |
| Shareholder’s Equity | 942 | 1,189 | 996 | 1,354 |
| Total Assets | 1,790 | 1,965 | 2,010 | 2,171 |
| Previous Quarter ending 12/31/23 | Current Quarter ending 03/31/24 | Next Quarter ending 06/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 16 | 12 | 12 | 15 | 12 |
| Average Estimate | 0.066 USD | 0.070 USD | 0.071 USD | 0.300 USD | 0.371 USD |
| Year Ago | 0.070 USD | 0.070 USD | 0.070 USD | - | 0.300 USD |
| Publish Date | 2/29/2024 | 5/8/2024 | 8/7/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 15 | 12 | 12 | 17 | 14 |
| Average Estimate | 194 USD | 193 USD | 196 USD | 789 USD | 847 USD |
| Year Ago | 184 USD | 184 USD | 190 USD | - | 789 USD |
| Publish Date | 2/29/2024 | 5/8/2024 | 8/7/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
GoodRx Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Nabiey Romin | 01/14/2024 | 1,068.00 | 102,068.00 | 6.64 | Sell | No |
| Nabiey Romin | 01/14/2024 | 2,606.00 | 103,136.00 | n/a | Buy | No |
| Voermann Karsten | 12/07/2023 | 24,757.00 | 175,128.00 | 5.94 | Sell | No |
| Nabiey Romin | 12/07/2023 | 3,528.00 | 100,530.00 | 5.94 | Sell | No |
| Voermann Karsten | 12/07/2023 | 54,064.00 | 199,885.00 | n/a | Buy | No |
| Nabiey Romin | 12/07/2023 | 10,200.00 | 104,058.00 | n/a | Buy | No |
| Wagner Scott | 11/29/2023 | 21,652.00 | 182,900.00 | 5.76 | Buy | No |
| Wagner Scott | 11/28/2023 | 26,348.00 | 161,248.00 | 5.90 | Buy | No |
| Wagner Scott | 11/27/2023 | 4,157.00 | 134,900.00 | 6.00 | Buy | No |
| LeSieur Stephen | 11/19/2023 | 11,549.00 | n/a | 5.47 | Sell | No |
| LeSieur Stephen | 11/19/2023 | 20,487.00 | n/a | 5.47 | Sell | No |
| LeSieur Stephen | 11/19/2023 | 11,967,964.00 | n/a | 5.47 | Sell | No |
| LeSieur Stephen | 11/19/2023 | 11,549.00 | 11,549.00 | n/a | Buy | No |
| LeSieur Stephen | 11/19/2023 | 20,487.00 | 20,487.00 | n/a | Buy | No |
| LeSieur Stephen | 11/19/2023 | 11,967,964.00 | 11,967,964.00 | n/a | Buy | No |
| Wagner Scott | 11/16/2023 | 26,664.00 | 130,743.00 | 5.26 | Buy | No |
| Wagner Scott | 11/15/2023 | 104,079.00 | 104,079.00 | 5.16 | Buy | No |
| Nabiey Romin | 11/07/2023 | 4,379.00 | 93,858.00 | 5.40 | Sell | No |
| Beri Raj | 11/07/2023 | 17,507.00 | 263,514.00 | 5.40 | Sell | No |
| Nabiey Romin | 11/07/2023 | 12,663.00 | 98,237.00 | n/a | Buy | No |
| Beri Raj | 11/07/2023 | 31,657.00 | 281,021.00 | n/a | Buy | No |
| Bezdek Trevor | 10/21/2023 | 3,794,802.00 | 4,864,258.00 | n/a | Buy | No |
| Hirsch Douglas Joseph | 10/21/2023 | 3,794,802.00 | 4,864,258.00 | n/a | Buy | No |
| Nabiey Romin | 10/14/2023 | 902.00 | 85,574.00 | 5.31 | Sell | No |
| Nabiey Romin | 10/14/2023 | 2,606.00 | 86,476.00 | n/a | Buy | No |
GoodRx Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2021 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2020 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2019 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2018 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2017 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
| 2016 | GoodRx Holdings Inc Registered Shs -A- | - | - | USD |
*Yield of the Respective Date
GoodRx Holdings Inc Registered Shs -A- Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.066 USD | Q4 2023 Earnings Release | 02/29/2024 |
| Earnings Report | 0.070 USD | Q1 2024 Earnings Release | 05/08/2024 |
| Earnings Report | 0.071 USD | Q2 2024 Earnings Release | 08/07/2024 |
| Earnings Report | - | Q3 2024 Earnings Release | 11/06/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 02/26/2025 |
GoodRx Holdings Inc Registered Shs -A- Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.060 USD | Q3 2023 Earnings Release | 11/09/2023 |
| Press Conference | - | - | 11/09/2023 |
| Press Conference | - | - | 08/09/2023 |
| Press Conference | - | - | 05/10/2023 |
| Press Conference | - | - | 02/28/2023 |
GoodRx Profile
GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2015 and is headquartered in Santa Monica, CA.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
GoodRx Shareholder
| Owner | in % |
|---|---|
| Freefloat | 80.79 |
| Vanguard Group, Inc. (Subfiler) | 9.30 |
| The Vanguard Group, Inc. | 9.00 |
| Trevor Bezdek | 5.40 |
| Douglas Joseph Hirsch | 5.40 |
| Light Street Capital Management LLC | 4.54 |
| Silver Lake Group LLC | 3.82 |
| Andrew slu*tsky | 3.47 |
| Morgan Stanley Instl. Fund-Growth Portfolio | 3.44 |
| Morgan Stanley Instl. Fund Tr. - Discovery Portfolio | 3.15 |
| Renaissance Technologies LLC | 2.96 |
| Abdiel Capital Advisors LP | 2.81 |
| Columbia Management Investment Advisers LLC | 2.74 |
| Vanguard Total Stock Market ETF | 2.53 |
| Brighthouse Fds. Trust I - Morgan Stanley Discovery Portfolio | 2.50 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
As an enthusiast and expert in financial markets and stock analysis, I'll delve into the details of the provided information about GoodRx Holdings Inc. and related concepts.
Stock Performance Analysis:
1. Closing Price and Market Capitalization:
- On Friday, 01/26/2024, the closing price of GoodRx Holdings Inc Registered Shs -A- share was $6.52 on NAS.
- The market capitalization is $2.73 billion with 92.40 million shares outstanding.
2. Stock Price Movements:
- The stock showed a gain of 0.77%, with an opening price of $6.47 and a closing price of $6.52.
3. 52-Week Performance:
- The 52-week low for GoodRx stock was $4.14, and the stock is currently 157.68% away from the 52-week low.
- The 52-week high was $9.37, and the stock is 69.62% away from the 52-week high.
4. Analyst Ratings:
- GoodRx stock has a consensus rating of "hold," based on 22 buy ratings, 48 hold ratings, and 1 sell rating.
5. Analyst Price Forecasts:
- Analysts have a median target of $11.50 for GoodRx stock, with a high estimate of $35.00 and a low estimate of $4.50.
6. Current Stock Snapshot:
- Bid: $17.81, Bid Size: 500.00
- Ask: $17.93, Ask Size: 500.00
- Volume: 761,934.00
- Market Cap: $2.73 billion
- Day Low: $6.44, Day High: $6.61
Financial Metrics:
1. Dividend and P/E Ratio:
- Dividend: $0.00
- P/E Ratio: 15.53
- EPS 2024: $2.22
2. Earnings and Revenue Estimates:
- Analysts estimate GoodRx's revenue for 2024 at $789 million.
- EPS estimates for 2024 range from $0.066 to $0.300.
3. Insider Activity:
- Recent insider activities include both buying and selling by individuals like Nabiey Romin, Karsten Voermann, and Scott Wagner.
Analyst Opinions and Recommendations:
1. Recent Analyst Opinions:
- Recent opinions include a "Hold" rating from RBC Capital Markets and a "Sell" rating from Bank of America Merrill Lynch.
2. Historical Analyst Opinions:
- A history of analyst opinions reflects a mix of "Hold," "Buy," and "Sell" recommendations over time.
Corporate Information:
1. Company Profile:
- GoodRx Holdings, Inc. operates as a consumer-focused digital healthcare platform, providing transparent medication prices and telehealth services.
2. Shareholder Information:
- The top shareholders include Vanguard Group, Trevor Bezdek, Douglas Joseph Hirsch, Light Street Capital Management LLC, and others.
Conclusion:
In conclusion, GoodRx's stock performance is analyzed through various metrics, including historical prices, analyst recommendations, and financial indicators. The company's revenue and earnings estimates, along with insider activities, provide a comprehensive view for potential investors or those monitoring the stock. Always conduct thorough research and consider various factors before making investment decisions.
